PROCEPT BioRobotics Corporation Common Stock (PRCT) is a publicly traded Healthcare sector company. As of May 21, 2026, PRCT trades at $28.15 with a market cap of $1.48B and a P/E ratio of -16.03. PRCT moved +8.57% today. Year to date, PRCT is -15.13%; over the trailing twelve months it is -52.50%. Its 52-week range spans $19.35 to $103.81. Analyst consensus is buy with an average price target of $36.50. Rallies surfaces PRCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AUA Guidelines Back Aquablation for 30–150 mL Prostates with 5-Year Data: PROCEPT BioRobotics announced that the American Urological Association’s updated guidelines strengthen its recommendation for Aquablation therapy as a surgical option for men with prostate volumes of 30–80 mL and recognize its use in 80–150 mL prostates. Randomized trials show durable urinary symptom and flow rate improvements through five years.
| Metric | Value |
|---|---|
| Price | $28.15 |
| Market Cap | $1.48B |
| P/E Ratio | -16.03 |
| EPS | $-1.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $103.81 |
| 52-Week Low | $19.35 |
| Volume | 58 |
| Avg Volume | 0 |
| Revenue (TTM) | $308.05M |
| Net Income | $-95.57M |
| Gross Margin | 63.70% |
11 analysts cover PRCT: 0 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $36.50.